17 hours ago
1
Nemes Laszlo/iStock via Getty Images
Genentech, a Roche Group company (OTCQX:RHHBY) (OTCQX:RHHBF), said on Tuesday that a U.S. FDA advisory committee voted against approving bispecific antibody Columvi for those with relapsed or refractory diffuse large B-cell Lymphoma.
The company has submitted a supplemental biologics license
English (US) ·